AtriCure Revenue and Competitors
Estimated Revenue & Valuation
- AtriCure's estimated annual revenue is currently $500.8M per year.
- AtriCure received $88.4M in venture funding in October 2018.
- AtriCure's estimated revenue per employee is $401,600
- AtriCure's total funding is $8.5M.
Employee Data
- AtriCure has 1247 Employees.
- AtriCure grew their employee count by 18% last year.
AtriCure's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Cardiac VP | Reveal Email/Phone |
2 | CEO & President | Reveal Email/Phone |
3 | Chief IP Counsel | IP Attorney, Strategist | Reveal Email/Phone |
4 | VP Finance | Reveal Email/Phone |
5 | VP, Clinical Affairs and Biometrics | Reveal Email/Phone |
6 | VP, Human Resources | Reveal Email/Phone |
7 | VP, Service & Sales Operations | Reveal Email/Phone |
8 | VP Manufacturing Operations | Reveal Email/Phone |
9 | VP, Clinical Affairs - LARIAT | Reveal Email/Phone |
10 | VP Sales, Cryo Nerve Block | Reveal Email/Phone |
AtriCure Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $470.6M | 1875 | 1% | N/A | N/A |
#2 | $16.3M | 65 | -2% | N/A | N/A |
#3 | $7.8M | 31 | 0% | N/A | N/A |
#4 | $3.8M | 15 | 0% | N/A | N/A |
#5 | $21.1M | 84 | 4% | N/A | N/A |
#6 | $70M | 279 | 8% | N/A | N/A |
#7 | $4M | 16 | -11% | N/A | N/A |
#8 | $135.3M | 539 | 0% | N/A | N/A |
#9 | $11.5M | 46 | 5% | N/A | N/A |
#10 | $8.8M | 35 | 35% | N/A | N/A |
What Is AtriCure?
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator® Synergy Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals
$8.5M
Total Funding
1247
Number of Employees
$500.8M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AtriCure News
Analysts expect AtriCure, Inc. (NASDAQ:ATRC Get Rating) to announce ($0.27) earnings per share (EPS) for the current fiscal quarter,...
New clamp is designed to improve efficiency of concomitant ablation procedures. MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC),...
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib...
AtriCure, Inc.(NASDAQ:ATRC), a Mason, OH-based developer of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, is to acquire SentreHEART, Inc., a Redwood City, California-based developer of percutaneous left atrial appendage management solutions, for up to $300 ...
Other Companies in Mason
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $300M | 1303 | 8% | N/A |
#2 | $795.7M | 1610 | 6% | N/A |
#3 | $767.2M | 2414 | 4% | N/A |
#4 | $300M | 2988 | N/A | N/A |
#5 | $1451.7M | 3760 | 6% | $2.4M |
AtriCure Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-06-27 | $21.0M | 2nd | Article | |
| 2009-05-13 | $10.0M | Undisclosed | Article | |
| 2016-04-29 | $25.0M | Undisclosed | Silicon Valley Bank | Article |
| 2018-10-05 | $88.4M | Undisclosed | J.P. Morgan | Article |